Ellis Martin Report: Entheon Biomedical's (CNSX:ENBI) HaluGen Psychedelics Genetic Test Ahead of Ethical Clinical DMT Therapy
Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule.